Journal ArticleDOI
Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
Reads0
Chats0
TLDR
The evolution of crystal engineering into a form of supramolecular synthesis is discussed in this article in the context of problems and opportunities in the pharmaceutical industry, and it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.About:
This article is published in Chemical Communications.The article was published on 2004-08-31. It has received 1008 citations till now.read more
Citations
More filters
Journal ArticleDOI
Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
TL;DR: The concept and theory of crystal engineering is covered and the potential benefits, disadvantages and methods of preparation of co-crystals, metastable polymorphs, high-energy amorphous forms and ultrafine particles are discussed.
Journal ArticleDOI
Crystal Engineering: A Holistic View
TL;DR: Among the topics discussed are the nature of intermolecular interactions and their role in crystal design, the sometimes diverging perceptions of the geometrical and chemical models for a molecular crystal, the relationship of these models to polymorphism, knowledge-based computational prediction of crystal structures, and efforts at mapping the pathway of the crystallization reaction.
Journal ArticleDOI
Crystal engineering: from molecule to crystal.
TL;DR: This Perspective provides a brief historical introduction to crystal engineering itself and an assessment of the importance and utility of the supramolecular synthon, which is one of the most important concepts in the practical use and implementation of crystal design.
Journal ArticleDOI
Pharmaceutical Co-Crystals
TL;DR: This review addresses how crystal engineering has been applied to active pharmaceutical ingredients, API's, with emphasis upon how pharmaceutical co-crystals, a long known but little explored alternative to the four traditionally known forms of API, can be generated in a rational fashion.
Journal ArticleDOI
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
N. Jagadeesh Babu,Ashwini Nangia +1 more
TL;DR: In this article, the authors reviewed several novel examples of pharmaceutical cocrystals from the past decade and analyzed the enhanced solubility profiles of cocrystal profiles, showing that the peak dissolution for pharmaceutical cocystals occurs in a short time (<30 min), and high-solubility is maintained over a sufficiently long period (4-6 h) for the best cases.
References
More filters
Journal ArticleDOI
From molecules to crystal engineering: supramolecular isomerism and polymorphism in network solids.
Journal ArticleDOI
Supramolecular Synthons in Crystal Engineering—A New Organic Synthesis
TL;DR: In this article, the authors show that crystal engineering is a new organic synthesis, and that rather than being only nominally relevant to organic chemistry, this subject is well within the mainstream, being surprisingly similar to traditional organic synthesis in concept.
Journal ArticleDOI
Encoding and decoding hydrogen-bond patterns of organic compounds
Journal ArticleDOI
Photodimerization in the solid state
TL;DR: In this article, a review of solid-state photochemistry can be found under four parallel headings: first, analysis of the topochemical postulate according to which the course of the solid state reaction and the stereochemistry of the photodimer (if any) can be predicted from the configuration and nearest-neighbour geometry of closest monomer molecules in the crystal lattice; secondly, the study of the lOCUS of the reaction, that is the dependence of the course or (dimerization, cis trans isomerization) on crystal texture (dislocation